Publication | Open Access
Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease
32
Citations
32
References
2018
Year
ThrombosisHypertensionCardiovascular DiseaseHigh RiskPcsk9 InhibitionPharmacologyLipid-lowering TherapyHyperlipidemiaVascular BiologyPharmacotherapyMedicineAtherosclerosisDyslipidemiaPeripheral Vascular Disease
| Year | Citations | |
|---|---|---|
Page 1
Page 1